American biotechnology company Novavax has started the third phase of coronavirus vaccine trials. The company announced this on its website on Thursday, September 24.
It is noted that the research will take place in the UK and will last several weeks, up to 10 thousand people aged 18 to 84 years will take part in it.
On August 4, the U.S. company Novavax announced two successful trials of its own drug, which can be used as a vaccine against coronavirus. It was noted that the vaccine was well tolerated, the participants had a high level of antibodies without dangerous side effects.